New drug may help Alzheimer’s patients
Photo by Jiří Suchý | Unsplash
When people have Alzheimer’s disease, an estimated 20% to even 50% suffer from hallucinations and delusions; that is, they see or believe things that aren’t real or true.
It goes without saying that these symptoms are upsetting for not only the patient but everyone around them.
“These symptoms can be distressing for both patients and their caregivers. Researchers are studying whether this medication can safely help manage these symptoms and improve quality of life,” said Ronke Awojoodu, CEO, founder and research director at Patient First Clinical Trials in Lutherville, Maryland.
Fortunately, a new drug is being tested that could help. Manufactured by MapLight Therapeutics, a biotech company based in Redwood City, California, the drug passed its phase one safety trials two years ago and is now in phase two of development.
The clinical trial is under way in 40 locations, including in countries like Canada, France and South Korea. One of them is right here in our area: Patient First Clinical Trials on York Road.
“This study is evaluating whether an investigational medication can help reduce hallucinations and delusions in people living with Alzheimer’s disease,” Awojoodu said.
How the study works
The study requires seven in-person visits. Patients and their caregivers go to Patient First Clinical Trials to take the study drug. Free parking is available, and, for people without a car, free transportation (a ride from Lyft) is provided.
They’ll take a pill once a week for seven weeks. The study is “double-blind,” which means neither the patient nor staff know if the pill contains the drug or a harmless placebo.
After the seven weeks, staff will follow up with a phone call.
Why participate in a clinical trial?
If the drug successfully reduces symptoms, Awojoodu said, it could change the future for Alzheimer’s patients.
Patient First Clinical Trials has other studies underway now for conditions like high blood pressure, diabetes, allergies, asthma and COPD. Participants can make a big difference.
“Every treatment available today exists because someone chose to participate in a clinical trial,” she said.
“By taking part in this study, participants and their families can help researchers learn more about Alzheimer’s disease psychosis and contribute to the development of future treatment options. Their participation may help improve care for future patients and families facing similar challenges.”
For more information, email info@pfctrials.com or call (410) 832-3968.
